© The Financial Times Ltd 2015 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of Nov 21, 2015, the consensus forecast amongst 35 polled investment analysts covering AstraZeneca plc advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Nov 18, 2015. The previous consensus forecast advised that AstraZeneca plc would outperform the market.
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
Share price forecast information is not available for AstraZeneca PLC. View Full Financials
In 2014, AstraZeneca PLC reported a dividend of 2.80 USD, equaling last years dividend. The 31 analysts covering the company expect dividends of 2.77 USD for the upcoming fiscal year, a decrease of 1.07 %. View Full Financials
|Div growth (TTM)||0.00%|
On Nov 05, 2015, AstraZeneca plc reported 3rd quarter 2015 earnings of 1.03 per share. This result was in line with the consensus of the 14 analysts following the company and under-performed last year's 3rd quarter results by 1.90 %.
The next earnings announcement is expected on Feb 03, 2016. View Full Interim Financials
|Average growth rate||+2.86 %|
AstraZeneca plc reported annual 2014 earnings of 4.28 per share on Feb 05, 2015.
The next earnings announcement from AstraZeneca plc is expected the week of Feb 03, 2016. View Full Annual Financials
|Average growth rate||-9.98 %|
AstraZeneca PLC had 3rd quarter 2015 revenues of 5.95bn. This missed the 5.97bn consensus estimate of the 15 analysts following the company. This was 9.13 % below the prior year's 3rd quarter results. View Full Interim Financials
|Average growth rate||-2.21 %|
AstraZeneca PLC had revenues for the full year 2014 of 26.10bn. This was 1.49% above the prior year's results. View Full Annual Financials
|Average growth rate||-5.59 %|